Thalassemia major is a hereditary hemolytic disease with a *severe form of β-*thalassemia*.*It causes severe anemia after a *reduced production of β-globin chains* ([@B1]). Thalassemia belt is expanding in the eastern *coast of the Mediterranean region*, throughout the Arabian Peninsula, Turkey, Iran, India and the Southeast Asia ([@B2]). This disease is one of the most common hereditary diseases in Iran, and the number of patients with thalassemia major is about 18800 people ([@B3]). These patients regularly receive blood to prevent complications like chronic anemia and bone changes ([@B4]). Over the past 2-3 decades, blood transfusions have significantly increased lifetime and life expectancy in patients with thalassemia major ([@B5]). At the same time, the increasing use of this treatment has led to complications of iron overload ([@B6]). One of the toxic effects of iron overload occurs in the endocrine glands ([@B7]).

Even with careful management of patients, disorders of endocrine glands such as growth retardation, hypogonadism, insulin-dependent diabetes, hypothyroidism, hyporparathyroidism may occur ([@B8]-[@B11]). To prevent this complication of iron overload, chelation therapy regimens are used ([@B12]).

Endocrine gland complications may be due to the unsystematically iron chelation therapy in patients with thalassemia major in the developing countries ([@B10]). Diabetes is one of the most common and serious diseases that can be considered as the human's most important metabolic disease ([@B13]).

The most common complications of diabetes are cardiovascular diseases, retinopathy, neuropathy, nephropathy, sexual dysfunction and infection ([@B14]). The term impaired glucose tolerance (IGT) was introduced in 1979 by the National Diabetes Data Group (NDDG) as part of the classification and diagnostic criteria. Later on, this term was implemented by the World Health Organization (WHO) criteria ([@B15]).

Progress from normal glucose to type-II diabetes has often been an intermediate state associated with change glucose metabolism called IGT or pre-diabetes stage. IGT is a risk factor for type-II diabetes and patients with IGT without lifestyle change may develop to type-II diabetes in ten years ([@B16], [@B17]). Whereas pre-diabetes state was detected at early stage, diabetes can be delayed for several years with appropriate iron chelation therapy and regularly use of desferal ([@B18], [@B19]).

A simple review of the literature showed that the prevalence of diabetes, impaired fasting glucose (IFG) and IGT in patients with thalassemia major in Iran had been reported differently ([@B19]-[@B22]). Systematic review and meta-analysis study of the review of all literature and combining them can be a comprehensi veview of the problem in a specific population ([@B23]-[@B25]). Because of no available comprehensive report, this study assesses the prevalence of diabetes, IFG, and IGT in patients with thalassemia major in Iran.

Methods
=======

This review was conducted based on PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guideline ([@B24]). To avoid bias, all steps of the study including search, selection of studies, quality assessment, and data extraction were conducted by two researchers, independently. Any disagreement was reviewed by third researcher.

**Search Strategy:** To obtain the related documents in Persian and English, scientific databases such as Magiran, Iranmedex, SID, Medlib, IranDoc, Scopus, PubMed, Science direct, Cochrane, Web of Science, Springer, Wiley Online Library, and Google Scholar were searched until December 2015. Persian and English MeSH keywords were used. Prevalence, diabetes, Glucose Intolerance, prediabetes, endocrine disorders, ferritin, hemosiderosis, iron overload, chelation therapy, endocrine, Iran, thalassemia major and also word combination of and & or operators were used as keywords.

**Inclusion Criteria:**Related papers about the prevalence of diabetes, IFG, and IGT in thalassemia major patients in both English and Persian Language were considered as inclusion criteria. Diabetes was determined according to World Health Organization (WHO) and American Diabetes Association (ADA). The criterion for the diagnosis of IFG was determined as 100≥FBS\<126 mg/dl while the criterion for IGT was determined as two-hour glucose levels of 7.8-11.1 mmol/L(140-200 mg/dl) on the 75 g oral glucose tolerance test ([@B26]).

**Exclusion Criteria:** Studies with non-randomly selected sample size; lack of relevance to the topic; letters to the editor and case report studies.

**Evaluation of Quality:**Researchers using a *STROBE* *standard checklist*([@B27]) including 22 items. The selected studies were appraised in all aspects of methodology including sampling methods, measurement parameters, statistical analysis and objectives of the study. The minimum and maximum scores in this checklist were 16 and 44, respectively. The papers that had reached the minimum score ([@B16]) were selected for the meta-analysis stage.

**Study Selection:**In the initial search, 420 studies probably related to the prevalence of diabetes, IFG, and IGT in patients with thalassemia major were found of which 210 studies were excluded because they were duplicate papers (papers extracted by two researchers with identical titles, authors, and journal). From the remaining 210 studies, 189 cases were excluded after reading the summary and the full text of the paper due to non-relevance of the topic, and the lack of criteria and low quality ([figure 1](#F1){ref-type="fig"}).

![The entrance steps of systematic review and meta-analysis](cjim-8-001-g001){#F1}

**Data Extraction:**All final papers imported to study process were extracted by a pre-prepared checklist. The checklist includes the author name, year of study, place of study, type of study, sample size, prevalence of diabetes, IFG and IGT, prevalence of diabetes, IFG and IGT according to gender, *diagnostic criteria for*diabetes, IFG and IGT and mean of serum ferritin level in diabetes and control groups.

**Statistical Analysis:**The variance of each study was calculated according to the binomial distribution. According to the sample size and variance, the studies were combined. To assess the heterogeneity of the studies, Cochran test, and I^2^ index was used. The heterogeneity of the study was 84.8% classified among studies with high heterogeneity (I^2^ index less than 25%: low heterogeneity, 25%-75%: average heterogeneity and more than 75%: high heterogeneity). Due to the heterogeneity of the studies, the random effects model was used to combine studies. To find the source of heterogeneity among studies, meta-regression model was used for the year of study, sample size, quality of studies and diagnostic method. To investigate propagation bias, Beggs test and draw of funnel plot were used. Data were analyzed using the Stata Version 11.1 software. The significance level was considered as p\<0.05.

Results
=======

In a systematic review of studies, 32 studies were included into the meta-analysis process. All participants in the study were 3959 with thalassemia patients in an average age of 16.83 years (95% CI: 15.71-17.94) ([table 1](#T1){ref-type="table"}).

###### 

Detailed characteristics of 32 articles included in the systematic review on the prevalence of diabetes, IFG and IGT in patients with thalassemia major

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Ref.**   **Author Name**      **Place of study**          **Year of study**   **Sample size**   **Age**\        **Diagnostic criteria for diabetes**   **Prevalence of Diabetes** **(%)**   **Prevalence of** **IGT (%)**   **Prevalence of** **IFG (%)**
                                                                                                    **(Mean±SD)**                                                                                                               
  ---------- -------------------- --------------------------- ------------------- ----------------- --------------- -------------------------------------- ------------------------------------ ------------------------------- -------------------------------
  ^19^       Najafipour           Tabriz                      2006                65                15.6±4.4        DAD and WHO                            8.9                                  7.1                             28.8

  ^20^       Rostami              Bushehr                     2009                60                20.23±23        WHO                                    18.3                                 6.7                             

  ^21^       Safari               Qazvin                      2006                63                20.89±5.01      DAD                                    25.4                                                                 

  ^22^       Rezaei               Kohgiluyeh va boyer ahmad   2003                233               13.24±6.1       DAD                                    3.1                                                                  4

  ^28^       Kashanchi Langarod   Karaj                       2010                184               19.64±7.06      DAD                                    10.22                                                                12.4

  ^29^       Najafipour           Tabriz                      2005                56                15.6±4.25       DAD and WHO                            8.9                                  7.1                             30

  ^30^       Company              Ahwaz                       2003                195               14.9±6.09       DAD and WHO                            16.4                                 19                              

  ^31^       Kawsarian            Sari                        1996                70                                DAD and WHO                            28.5                                 15.7                            1

  ^32^       Mortazavi            Zanjan                      1991                146                               DAD and WHO                            2.7                                  6.2                             

  ^33^       Soheili Kha          Yazd                        1998                53                10.7            DAD                                    3.7                                                                  

  ^34^       Keihanian            Tehran                      2010                133               18.28           DAD                                    6                                                                    

  ^35^       Azimi                Tehran                      2003                45                                DAD and WHO                            11.1                                                                 

  ^36^       Mahdavi Anari        Tehran                      1999                60                                DAD                                    8.3                                                                  

  ^37^       Fotoohi              Tehran                      1999                60                                DAD and WHO                            18.3                                 8.3                             

  ^38^       Younesi              Qazvin                      1998                94                                DAD                                    5.3                                                                  

  ^39^       Yazdi                Yazd                        2005                65                10.3            DAD                                    8.3                                  18.3                            

  ^40^       Haghverdi            Sari                        1998                20                                DAD                                    5                                                                    20

  ^41^       Shiva                Tabriz                      2006                71                12.9±5.2        DAD and WHO                            8.5                                  21.1                            

  ^42^       Ishraqi              Babol                       2010                280               19.6±8.5        DAD and WHO                            13.9                                                                 

  ^43^       Jahantigh            Zahedan                     2011                346               17.7±4.9        DAD and WHO                            15.9                                 6.6                             

  ^44^       Faalpur              Ardebil                     2002                51                                WHO                                    3.9                                  3.9                             

  ^45^       Saffari              Qazvin                      2012                77                21.26±4.53      WHO                                    16.9                                 13                              

  ^46^       Arjmandi Rafsanjan   Tehran                      2004                273                               DAD                                    18.3                                                                 

  ^47^       Eshghi               Zahedan                     2001                66                                DAD and WHO                            4.5                                  3                               

  ^48^       Moayeri              Tehran                      2006                158               4.8             DAD                                    10.1                                                                 

  ^49^       Karamifar            Shiraz                      2003                150                               DAD                                    7.3                                                                  

  ^50^       Mowla                Sari                        2004                98                4               DAD                                    8.2                                                                  

  ^51^       Shams                Tehran                      2009                78                16±6            DAD                                    5.1                                                                  12.8

  ^52^       Karimi               Shiraz                      2008                47                19.7±5.3        DAD and WHO                            19                                                                   

  ^53^       Raissi               Shahrekord                  2003                40                                DAD and WHO                            10                                                                   

  ^54^       Sadat                Gorgan                      2007                185                               DAD                                    11.9                                                                 

  ^55^       Mehrvar              Tehran                      2004                437                               DAD                                    6.2                                                                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Diabetes:**The prevalence of diabetes in patients with thalassemia major in Iran was estimated as 9% (95% CI: 6.8-10.5). The lowest prevalence of diabetes is associated with *Arjmandi\'s*(2004) in Tehran (1.8%) and the highest prevalence of diabetes was reported in Safari's (2006) in Qazvin (25.4%) ([figure 2](#F2){ref-type="fig"}).

![Forest plots presenting the prevalence of diabetes in patients with thalassemia major. Weights are assessed from the random-effects model analysis](cjim-8-001-g002){#F2}

The prevalence of diabetes in patients with thalassemia major had been examined in 7 studies according to sex. This rate was estimated as 12.6% (95% CI: 6.1-19.1) in males and 10.8% (95% CI: 8.2-14.5) in females.

The prevalence of diabetes in patients with thalassemia major was indicated according to the geographical regions in [figure 3](#F3){ref-type="fig"} and shows that the lowest prevalence was in the West of Iran (5%) in which the highest prevalence rate was in South (14.3%).

In terms of the diagnostic criteria for diabetes, the lowest and the highest prevalence rates are related to *DAD* (7%) and the history of insulin therapy (13%) ([table 2](#T2){ref-type="table"}).

![Forest plots presenting the prevalence of diabetes in patients with thalassemia major sub-grouped by geographical regions.](cjim-8-001-g003){#F3}

###### 

Estimates for prevalence of diabetes in patients with thalassemia major according to diagnostic criteria for diabetes

  **Diagnostic criteria**   **(N) studies**   **Sample size**   **I** ^2^ **(%)**   **Confidence interval (%)**   **Overall prevalence (%)**
  ------------------------- ----------------- ----------------- ------------------- ----------------------------- ----------------------------
  DAD                       16                2284              73.3                5-9                           7
  WHO                       3                 188               80.7                2-13                          12
  WHO And DAD               13                1487              82.7                6-13                          10

Regression model was used to investigate the relationship between prevalence of diabetes with the year of study and sample size. The p-values were calculated 0.382 and 0.326, respectively and no statistically significant was found ([figure 4](#F4){ref-type="fig"}).

In [figure 5](#F5){ref-type="fig"} publication bias is shown as symmetry in a funnel plot and bias is not involved in these studies (P=0.345). In [figure 6](#F6){ref-type="fig"} the relationship between prevalence of diabetes with studies of quality was provided and p-values were calculated 0.187 and no significant relationship was observed in this regard. In 4 studies investigated, between serum ferritin levels and diabetes, no significant relationship was found (p\<0.05) ([figure 7](#F7){ref-type="fig"}).

**IFG:**The prevalence of IFG in patients with thalassemia major in Iran was shown in [figure 8](#F8){ref-type="fig"} and this rate was estimated as 12.9% (95% CI: 7-18.8).

![A: Meta-regression plot of the prevalence of diabetes based on the year of study (P=0.382). B: Meta-regression plot of the prevalence of diabetes based on sample size of the study (P=0.362](cjim-8-001-g004){#F4}

![Publication bias for the prevalence of diabetes in patients with thalassemia major (P=0.435). The size of circles shows the weight of studies (bigger circles represent more samples](cjim-8-001-g005){#F5}

![Meta-regression plot of the prevalence of diabetes based on the quality of the study (P=0.187](cjim-8-001-g006){#F6}

![Forest plots presenting the relationship between serum ferritin level and diabetes based on a random effects model in the meta-analysis. SMD indicates the standardized mean difference](cjim-8-001-g007){#F7}

![Forest plots presenting the prevalence of impaired fasting glucose in patients with thalassemia major](cjim-8-001-g008){#F8}

**IGT:**In 13 studies, the prevalence of IGT in patients with thalassemia major in Iran was estimated 9.6% (95% CI: 6.6-12.5). The lowest prevalence of IGT was related to a study in 2001 in Zahedan (3%) and the highest prevalence of IGT was related to a study in 2006 in Tabriz (21.1%). In 5 studies, the prevalence of IGT in patients with thalassemia major had been investigated according to sex estimated in males & females as 6.5% (CI 95%: 1.6-11.3) and 10.2% (CI 95%: 6.1-14.3), respectively ([figure 9](#F9){ref-type="fig"}). The relationship between IGT in patients with thalassemia major with the year of study and sample size, meta-regression model was used and the p-values were calculated 0.702 and 0.736, respectively and no significant correlation was found ([figure 10](#F10){ref-type="fig"}).

![Forest plots presenting the prevalence of impaired glucose tolerance in total (A) male (B) and female (C) patients with thalassemia major](cjim-8-001-g009){#F9}

![A: Meta-regression plot of the prevalence of IGT based on the year of study (P=0.702). B: Meta-regression plot of the prevalence of IGT based on sample size of the study (P=0.736](cjim-8-001-g010){#F10}

Discussion
==========

The overall prevalence of diabetes in patients with thalassemia major was estimated 9 percent, the prevalence of diabetes in patients with thalassemia major in other countries was reported 6-27%, (Such as: United Arab Emirates (10.5%), Oman (27%), Taiwan (26.8%), South America (14%) and Italy (6.5%) (56-60). Genetic, geographical, cultural and economic factors as well as the quality of blood transfusion and chelation therapy, especially onset and the rate of the desferal dosage can be causes of different in reporting prevalence in various countries. . A systematic review of Iranian thalassemia patients has reported the regular iron chelation therapy as 54%. Therefore, chelation therapy in many patients with thalassemia major in Iran has been done unsystematically that must be considered ([@B61]).

The difference in reporting the prevalence of diabetes in patients with thalassemia major in Iran was 1.8-34% and it seems the most prospective reason for this difference, different diagnostic criteria. Therefore, the subgroup analysis was performed on diagnostic criteria and most studies (16 studies) had used ADA criteria, and this rate was estimated 7% and was not significantly different. Also, in the results of meta-regression model, no significant difference was found based on diagnostic criteria (P=0.343).

In a systematic review study in Iran, the prevalence of diabetes among adults is 3% and 16.8%, respectively for the age range of 25-34 and 55-64-years-old ([@B62]). In another review study in Iran, the prevalence of diabetes among the 15-25 years-old (young society) has been reported about 3.6% ([@B63]).  And both studies indicated the incidence of diabetes *significantly increases with age*. In the present study, the age range of patients was 10-20 years-old (mean age of 16.8), which the prevalence of diabetes was estimated 9% that is more than the non-thalassemic population with same age. In some studies, the obvious role of iron overload has been proven in the endocrine glands including pancreas in the pathogenesis of diabetes ([@B64],[@B65]) and other studies have shown that insulin resistance and lack of insulin are the two reasons of pre-diabetes and diabetes in this patients ([@B66], [@B67]). Endocrine complications in patients with thalassemia major mostly happen in their second decade of life. The highest prevalence of diabetes is reported in Razavi (33.9%) ([@B22]), Saffari (25.4%) ([@B21]) and Rabbani's (25.4%) ([@B32]), and the lowest prevalence occurred in Arjmandi (1.8%) ([@B41]) and Mortazavi (2.7%) ([@B27]) and the results were not highly different in terms of average age of subjects participating in studies but the prevalence of diabetes was variable that can indicate different therapeutic follow-ups of these patients in different parts of Iran. The most comprehensive study in terms of sample size and examination areas in Iran was in Mehrvar's et al. ([@B50]) in 2004 with a sample size of 407 thalassemia patients in Shiraz was reported a prevalence of diabetes as 6.6% which was consistent with the present results. The prevalence of diabetes in male patients with thalassemia major (12.6%) is more than female patients (10.8%), but this difference was not significant. A review study in the general population of Iran has estimated the prevalence of diabetes in males and females, 1.7% and 3.8%, respectively ([@B62]), which was inconsistent with results of this study. The most obvious reason can be the role of iron overload in thalassemia patients that its pathogenesis has been proven in endocrine disorders ([@B7]).

The prevalence of diabetes in patients with thalassemia major in studies of high and moderate quality was estimated as 9% and 11%, respectively and results of, no significant correlation was found between the prevalence of diabetes and quality of studies (P=0.187) in meta-regression model, which poor-quality studies can be the cause of that.

In the present study, in the relationship between serum ferritin level and diabetes, a mean difference of serum ferritin in case and control groups was estimated as -0.3 (95% CI:-49 to 43) and was not a significant. In other studies, different results were reported, in Mula-Abed['s et al.]{.ul}([@B57]) there was not a significant relationship but in Borgna's ([@B64]) and Gamberini's studies ([@B65]) there was a significant relationship. The prevalence of IFG in patients with thalassemia major in Iran was estimated to be 9.6%. In a review study, the prevalence of IFG in the adult population of Iran has been reported as 16.8% ([@B62]) and it also showed that with increasing age, the prevalence was increased. Due to the small number of studies, could not do a sub-group analysis on the prevalence of IFG.

The overall prevalence of IGT in Iranian patients with thalassemia major was estimated as 9.6%. Due to the low number of studies, we could not sub-group based on the IGT. The prevalence of this disorder in other countries including Turkey (2.2%), Italy (6.5%), Thailand (12.5%) and Egypt (24.1%) was variable ([@B68]-[@B71]).

The prevalence of IGT in patients with thalassemia major in 5 studies under review on females (10.2%) was more than males (6.5%). However, this difference was not significant.

Meta-regression model for finding the source of heterogeneity among studies was used, and meta-regression results in a year of studies and sample size for diabetes and IGT prevalence was not statistically significant. During years of studies (1991-2015), the prevalence of diabetes and IGT has been almost constant. Constant prevalence of the diseases over the last 24 years, and also the high prevalence of diabetes in patients with thalassemia major, attention, and follow-up in this patient seems necessary.

No relationship between serum ferritin and development of diabetes was noted. Jiang et al. was found a strong relationship between ferritin and diabetes ([@B72]), also high ferritin level is associated with cardiovascular disease, hepatic steatohepatitis and central adiposity ([@B72]-[@B74]).

Publication bias for studies entering the meta-analysis process has been shown as symmetry in Funnel plot in which the p-value was 0.345, indicating that the possibility of publication bias is not statistically significant.

Research limitations**:**1. The inability of internal databases for searching the combined keywords. Thus, we cannot use the keywords in combination; 2. Because of no the prevalence of diabetes, IFG, and IGT by age reported in studies, we could not calculate the prevalence based on age; 3. Since desferal dosage and intervals of blood transfusion were not reported in most studies, we could not calculate the relationship between these variables with diabetes, IFG and IGT; and 4. Due to the limited number of studies, we could not do a subgroup analysis of studies on the prevalence of IFG and IGT.

In conclusion the prevalence rates of diabetes, IFG, and IGT are high in Iranian patients with thalassemia major. Therefore, more effective protocols and management strategies which include improved protocols, blood transfusion, chelation therapy, educating and enhancing awareness of the parents and patients about iron overload complications seem to be essential to minimize endocrine complications. In addition, screening for the early diagnosis of endocrine complications once every six-month should be done as suggested by the Thalassemia International Federation.
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